Compare OSUR & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | MGTX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.6M | 1.2B |
| IPO Year | 2000 | 2018 |
| Metric | OSUR | MGTX |
|---|---|---|
| Price | $3.51 | $12.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $3.00 | ★ $24.57 |
| AVG Volume (30 Days) | 439.4K | ★ 700.7K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | ★ $167,064,000.00 | $81,391,000.00 |
| Revenue This Year | $4.48 | $141.38 |
| Revenue Next Year | $7.76 | N/A |
| P/E Ratio | ★ N/A | $9.82 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $2.08 | $6.62 |
| 52 Week High | $4.58 | $15.35 |
| Indicator | OSUR | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 40.79 |
| Support Level | $2.86 | $12.39 |
| Resistance Level | $4.29 | $15.33 |
| Average True Range (ATR) | 0.13 | 0.55 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 48.84 | 10.74 |
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.